ABSTRACT

There are plentiful management trials in Oral Submucous Fibrosis (OSMF), such as drugs, herbs, and Chinese medicines, but none proved to be entirely successful. So in this review, there are different management strategies tried in the management of OSMF, mechanism of action, and the dosage regimen.

Keywords: Oral submucous fibrosis (OSMF); potentially malignant disorder; management.

1. INTRODUCTION

Oral submucous fibrosis (OSMF) is a chronic disease associated with significant functional morbidity and an increased risk for malignancy. OSMF predominantly affects the Asian population and Asian migrants living in other parts of the World [1].

But in most of the research the management of OSMF was based on Clinical, Histopathological and functional staging proposed by several authors [2].

The management of OSMF has been discussed previously by several authors [3,4,1]. This Review updates the different management protocols available and tried for OSMF.

2. VARIOUS MANAGEMENT OF OSMF IS CATEGORIZED AS FOLLOWS

1. Habit counseling
2. Basic regimen
3. Medical management
4. Physiotherapy

Review Article

Received 10 October 2021
Accepted 14 December 2021
Published 15 December 2021

 Management Strategies for Oral Submucous Fibrosis- An Update

R. Sudarshan a*#

a Meenakshi Academy of Higher Education and Research, West K.K Nagar, Chennai, India.

Author’s contribution

The sole author designed, analysed, interpreted and prepared the manuscript.
### Table 1. Different drugs tried as management protocols are discussed in the table

| Sl no | Drugs                                      | Mechanism of action                                                                 | Duration                  | Dosage                        | Route of administration |
|-------|--------------------------------------------|--------------------------------------------------------------------------------------|---------------------------|-------------------------------|--------------------------|
| 1.    | Hydrocortisone [8]                         | Anti-inflammatory action by inhibiting the generation of inflammatory factors and increasing the apoptosis of inflammatory cells.² | once a week for 12 weeks  | 1.25 cc of injection hydrocortisone on each side | Intralesional             |
| 2.    | Dexamethasone [9]                          |                                                                                     | 10 weeks                  | 4 mg                          | Intralesional             |
| 3.    | Triamcinolone acetonide [10]               |                                                                                     | Divided doses at 10 day intervals for a period of 2-3 months | 150-200 mg                   | Intralesional             |
| 4.    | Triamcinolone diacetate [11]               |                                                                                     | 4 weeks                   | 10 mg/ml                      | Intralesional             |
| 5.    | Betamethasone [11]                         |                                                                                     | 6 hours for 3 weeks       | 0.5 mg/ml                     | Topical                  |
| 6.    | Prednisolone [12]                          |                                                                                     | 2-4 weeks                 | 20-30 mg                      | Systemic                |
| 7.    | Steroids and Physiotherapy [8].            | Microwave diathermy at 2450 MC/s and injection of hydrocortisone, vitamin A and B complex. | 20 minutes with 15 sittings | 20-25 Watts                   | Selective heating of Juxtaepithelial connective tissue (Madalli V et al., 2014) |
| 8.    | Vitamins and minerals [13]                 | The main action is eliminating the deficiency status and normalizing the cellular activity to prevent pathological mechanisms like carcinogenesis. The hypothesis of vitamin E mechanism ¹ ¹ ¹ ¹ ¹ ¹ | 6 weeks                   | Beta Carotene 50mg, vitamin A palmitate 2500 IU, vitamin E acetate, 10 IU with vitamin C, zinc, copper and manganese | oral                     |
| 9.    | Thiocystic acid [14]                       | Antioxidant                                                                          | 30 min before or 2 hours after food | 600-1800 mg daily. Iv Dose 300-600 mg | oral                     |
| 10.   | Placental extracts[9]                      | It is an aqueous extract of the human placenta that contains nucleotides, enzymes, vitamins, amino acids, and steroids. The mechanism through "biogenic stimulation, and by increasing the recovery [15]. | 10 weeks                  | 2 cc                          | Intralesional             |
| Sl no | Drugs | Mechanism of action | Duration | Dosage | Route of administration |
|-------|--------|---------------------|----------|--------|-------------------------|
| 11.   | Papain and urea [16] | Proteolytic enzymes breakdown the inappropriate connective tissue fibrosis [1]. | 2 to 3 times daily for 15 days | 100 gms urea and 100 gms papain | Intraoral |
| 12.   | Chymotrypsin [9] | Proteolytic enzymes breakdown the inappropriate fibrosis [1]. | Biweekly | 5000 IU | Intralesional |
| 13.   | Hyaluronidase [9] | | Biweekly for 10 weeks once a week for 6 weeks | 1500 IU | Intralesional |
| 14.   | Collagenase [17] | | 1 ml of collagenase (1% solution) mixed with 1 ml of xylocaine | | Intralesional |
| 15.   | Borneol [18] | Anti-fibrosis activity inhibits fibroblasts. Mitosis, collagen, and TIMP-1 production and can be used as a penetration enhancer [18]. | Incubation period of 24, 48 and 72 hours. | Serial dilution of borneol (18.75, 37.5, 75, 150–300 lg/ml) | Penetration enhancing effects tried in mice fibroblast Invitro study |
| 16.   | Nylidrin hydrochloride [19] | Nylidrin relaxes and dilates the blood vessel ensures more excellent blood supply to ischemic tissues with little or no change in the blood pressure and heart rate [19]. | 3-8 weeks | 6 mg | Oral |
| 17.   | Pentoxifylline [20] | It is a methylxanthine derivative with vasodilating properties and was envisaged to increase mucosal vascularity Rajendran et al., [20]. | 3 times daily for 7 months | 400mg | Oral |
| 18.   | Buflomedial hydrochloride [21] | The mechanism is through vasodilation, mild anticoagulant properties, immune modulation, and antioxidant properties have been reported [1]. | 4 weeks | 450 mg TID | Oral |
| 19.   | Xantinol nicotinate [22] | Peripheral vasodialator | 4 months | Biweekly | Intralesional |
| 20.   | Levamisole and vitamin A [23] | Immune modulation diminishes pro-fibrotic inflammation and enhances pro-fibrinolytic immune-mediated pathways [1]. | 4 days OD for one week followed by biweekly for one month | 150 mg of levamisole along with aqua sol caps 50000 iµ | Oral |
| 21.   | Interferon gamma [24] | IFN γ is an antifibrotic cytokine. | Twice a week for 8 weeks (15 intralesional injections) | Eutectic Mixture of Local Anesthetics cream for 15 minutes then followed by IFN- | Intralesional |
| Sl no | Drugs                                      | Mechanism of action                                                                 | Duration | Dosage                  | Route of administration |
|-------|--------------------------------------------|--------------------------------------------------------------------------------------|----------|-------------------------|-------------------------|
| 22.   | Immune milk [25]                           | It contains a highly active anti-inflammatory compound that suppressed the experimentally induced inflammation in animal models. | Twice a day for 3 months | 0.25 ml (50 mg) of   | Oral                    |
| 23.   | Turmeric [26]                              | Anti-inflammatory, antioxidant, anti-cancer properties.                                | 3 months | Turmeric Oil (600 mg TO mixed with 3 g Extracts of Turmeric/day) | Oral                    |
| 24.   | Lycopene [27]                              | Anticarcinogenic, antioxidant, highest physical quenching                              | 2 months | 16 mg                   | Oral                    |
| 25.   | Tea pigments and vitamins [28]             | The main action is by eliminating the deficiency status and normalizes the cellular activity to prevent pathological mechanisms like carcinogenesis [1]. | ????    | ????                    | ????                    |
| 26.   | Mangifera indica, Withania somnifera, Daucus carota, Glycyrrhiza glabra, Vitis vinifera, Emblica officinalis, Yashada bhasma, oils of Triticum sativum [22] | Herbal antioxidant formulation.                                                      | 3 months | 2 capsules Mangifera indica-94 mg, Withania somnifera-71 mg, Daucus carota-47 mg, Glycyrrhiza glabra-29 mg, Vitis vinifera-12 mg, Emblica officinalis-141 mg, Yashada bhasma-2.5 mg, oils of Triticum sativum 6.5 mg | Oral                    |
| 27.   | Aloe vera [30]                             | Antioxidant, anti-inflammatory, and immunomodulation                                  | 3 times daily for 3 months | 5 mg gel               | Topical                 |
| 28.   | Gold, Iodine and Arsenotyphoid [31]        | With the surgical cutting of bands, Large Internal doses and Injection respectively     |          |                         |                         |
| 29.   | Glucosidorum tripterygii totorum, vitamin A and E, nicotinic acid [32] | The main action is by eliminating the deficiency status and normalizes the cellular activity to prevent pathological mechanisms like carcinogenesis [1]. |          |                         |                         |
| 30.   | Danxuan koukang, salvia miltiorrhiza [33]  | The mechanism is through vasodilation, mild anticoagulant properties, immune modulation, and antioxidant properties have been reported [1]. |          |                         |                         |

**ALTERNATIVE MEDICINE**

**OTHERS**
| Sl no | Drugs | Mechanism of action | Duration | Dosage | Route of administration |
|-------|-------|---------------------|----------|--------|-------------------------|
| 31.   | Turmeric and black pepper [34] | Anti-inflammatory, antioxidant, anticarcinogenic, antifibrotic, immunomodulatory | 3 months | Turmeric 400 mg  Black pepper 100 mg  2 capsules TID | Oral |
| 32.   | Nigella sativa [34] | Anti-inflammatory, antioxidant, anticarcinogenic, antifibrotic, immunomodulatory | 3 months | 500 mg  2 capsules TID | Oral |
| 33.   | Spirulina in combination with isometric exercises/threaded tapered screw/mouth stretching device [35] | Antioxidant, anti-inflammatory and immunomodulation | 3 months | BID | Oral |
| 34.   | Pentoxifylline and garlic pearls [36] | Garlic has immunomodulation, vasodilator, antioxidant, anti-inflammatory, and chemopreventive Pentoxifylline has antifibrinolytic, immunomodulation, anti-TNF effect, and hemorheological properties. | 3 months | Pentoxifylline 400 mg and garlic pearls 0.25% BID | Oral |
4. Surgical management
5. Laser Management

2.1 Habit Counseling

The first and foremost treatment plan in OSMF is strict discontinuance of habit with motivation and intense counselling session for educating and creating awareness about the disease and its malignant potential [5].

2.2 Basic Regimen

The second line of approach for the management of OSMF is the nutritional supplementation like Vitamins and Iron. It has been observed in a study that majority of the OSMF patients has Vitamin B12 and Iron deficiency due to inability to eat [6].

2.3 Medical Management

The management of OSMF has significant challenges for treatment options. Even though several options are available still an established treatment regimen is lacking. So such treatment options available are discussed in Table 1. The medical management strategies are categorized with following heading as steroids, nutritional supplements, biogenic stimulators, enzymes, penetration enhancers, vasodilators, immunomodulators, alternative medicine and others. Future therapies suggested are molecular targeted therapies, Imatinib, Pirfenidone, nintedanib, Clostridium histolyticum collagenases, Simtuzumab, Hyperbaric Oxygen therapy, and personalized Medicine [7].

2.4 Physiotherapy

Physiotherapy over the affected area to generate heat and mouth opening has been tried. A study in 2009 conducted on Fifty-four Nepali OSMF patients was managed for four months by randomly assigning them to 3 groups. The first group of patients in the physiotherapy group were asked to do jaw exercises five times a day in which tongue spatulas were placed passively between anterior teeth, spatula number determined by comfortable mouth opening. An extra spatula was added every fifth day, but the spatula was tried on the tenth day in case of pain. The patient was subjected to analgesics 30 minutes before exercise to reduce the pain. The second group was treated with local injection of steroids, and the third group received no active treatment. The patients subjected to physiotherapy improved mouth opening compared to the other two groups [37].

2.5 Surgical Treatment

This form of modality is usually suggested during the severe form of OSMF and when the other forms of modality are unsuccessful. The common method of excision is scalpel which is considered to be the preparatory step for surgical treatment. Different surgical procedures tried are intraoral (tongue, palate, buccal fat pad), extraoral (temporal fascia, nasolabial), distant flaps, grafts, muscle myotomies and oral stents etc. Further a systematic review stated that the choice of procedure depends on the operator. [38].

2.6 Laser

A systematic review by Gondivkar SM et al. from various databases found that studies with Laser were used for stage II and III OSMF patients. Even though different Laser types and parameters were considered, all studies showed improvement in mouth opening ranging between 6.84mm to 23.7mm. Further two studies showed improvement in tongue protrusion, check flexibility, and reduction in burning sensation [39].

3. CONCLUSION

The treatment of OSMF is still not satisfactory. Therefore, further clinical trials with newer modalities and combinations are required to manage this potentially malignant disorder and to prevent its malignant transformation.

CONSENT

It is not applicable.

ETHICAL APPROVAL

As per international standard or university standard ethical approval has been collected and preserved by the authors.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Kerr AR, Warnakulasuriya S, Mighell AJ, Dietrich T, Nasser M, Rimal J, Jalil A, Bornstein MM, Nagao T, Fortune F,
Hazarey VH, Reichart PA, Silverman S, Johnson NW. A systematic review of medical interventions for oral submucous fibrosis and future research opportunities. Oral diseases, 2011;17 (Suppl 1):42–57.

2. Gupta H, Grover N, Tyagi N, Misra A. Classification Systems in Oral Submucous Fibrosis Patients: A Review. TMU J Dent. 2018;5(2):13-19.

3. Jiang X, Hu J. Drug treatment of oral submucous fibrosis: a review of the literature. Journal of oral and maxillofacial surgery: official journal of the American Association of Oral and Maxillofacial Surgeons. 2009;67(7):1510–1515.

4. Fedorowicz Z, Chan Shih-Yen E, Dorri M, Nasser M, Newton T, Shi L. Interventions for the management of oral submucous fibrosis. The Cochrane database of systematic reviews. 2008;4:CD007156.

5. Deshpande A, Kiran S, Dhillon S, Mallikarjuna R. Oral submucous fibrosis: a premalignant condition in a 14-year-old Indian girl. BMJ case reports. 2013:bcr2013200786.

6. Agarwal V, Maiti S. Prevalence and management of oral submucous fibrosis and its implications on prosthodontic treatment: A retrospective study. International Journal of Research in Pharmaceutical Sciences.2020;11(SPL3):1702-1709.

7. More CB, Jatti Patil D, Rao NR. Medicinal management of oral submucous fibrosis in the past decade- A systematic review. Journal of oral biology and craniofacial research, 2020;10(4):552–568.

8. Gupta DS, Gupta MK, Golhar BL. Oral submucous fibrosis – a clinical study and management by physiobrlysis (MWD). Journal Indian Dental Association. 1980;52:375-8.

9. Gupta D, Sharma SC. Oral submucous fibrosis--a new treatment regimen. Journal of oral and maxillofacial surgery: official journal of the American Association of Oral and Maxillofacial Surgeons. 1988; 46(10):830–833.

10. Khanna JN, Andrade NN. Oral submucous fibrosis: a new concept in surgical management. Report of 100 cases. International journal of oral and maxillofacial surgery. 1995;24(6):433–439.

11. Borle RM, Borle SR. Management of oral submucous fibrosis: a conservative approach. Journal of oral and maxillofacial surgery: official journal of the American Association of Oral and Maxillofacial Surgeons. 1991;49(8):788–791.

12. Laskaris G. Treatment of Oral Diseases: A Concise Textbook. Thieme: Newyork. 2004:130.

13. Gupta S, Reddi MVR, Harinath BC. Role of oxidative stress and antioxidants in etiopathogenesis and management of oral submucous fibrosis. Indian Journal of Clinical Biochemistry. 2004;19:138-14.

14. Bhandarkar GP, Shetty KY, Kulkarni A. Thiotic acid in oral submucous fibrosis (India's disease) - A better tomorrow. Journal of Stomatology, Oral and Maxillofacial Surgery. 2018;119(2):129–134.

15. Kisave P, Shekhar V, Babu PS. The study of placentrex and hydrocortisone as an adjunct treatment in oral submucous fibrosis. J Family Med Prim Care. 2020;9(5):2469-2474.

16. Gupta DS, Rameshwar D, Iqbal A. Treatment modalities in oral submucous fibrosis: how they stand today? Study of 600 cases. Indian J Oral Maxillofac Surg. 1992;7:43–47.

17. Lin HJ, Lin JC. Treatment of oral submucous fibrosis by collagenase: effects on oral opening and eating function. Oral Dis. 2007;13:407-13.

18. Dai JP, Chen J, Bei YF, Han BX, Wang S. Influence of borneol on primary mice oral fibroblasts: a penetration enhancer may be used in oral submucous fibrosis. J Oral Pathol Med. 2009;38(3):276-81.

19. Sharma JK, Gupta AK, Mukhiya RD, Nigam P. Clinical experience with the use of peripheral vasodilator in oral disorders. Int J Oral Maxillofac Surg. 1987;16:695-9.

20. Rajendra R, Rani V, Shaikh S. Pentoxifylline therapy: A new adjunct in the treatment of oral submucous fibrosis. Indian J Dent Res. 2006;17:190-8.

21. Lai DR, Chen HR, Lin LM, Huang YL, Tsai CC. Clinical evaluation of different treatment methods for oral submucous fibrosis. A 10-year experience with 150-cases. J Oral Pathol Med. 1995;240:402-06.

22. Singh BP, Mittal N, Sharma V, Palani. Evaluation of role of Oxitard capsules in the treatment of Oral Submucous Fibrosis. The Antiseptic. 2009;106:507-507.

23. Rao B. Oral submucous fibrosis- The Davangere Study. JIAOMR. 1993;4:11-22.

24. Haque MF, Meghji S, Nazir R, Harris M. Interferon gamma (IFN-γ) may reverse...
oral submucous fibrosis. J Oral Pathol Med. 2001;30:12-1.
25. Tai YS, Liu BY, Wang JT, Sun A, Kwan HW, Chiang CP. Oral administration from cows immunized with human intestinal bacteria leads to significant improvements of symptoms and signs in patients with oral submucous fibrosis. J Oral Pathol Med. 2001;30:618-25.
26. Hastak K, Lubri N, Jakhi SD. Effect of turmeric oil and turmeric oleoresin on cytogenetic damage in patients suffering from oral submucous fibrosis. Cancer Lett. 1997;116:265-9.
27. Kumar A, Bagewadi A, Keluskar V, Singh M. Efficacy of lycopene in the management of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103:207-13.
28. Li X, Tang J. Clinical treatment observation of tea pigment for oral submucous fibrosis. Hua Xi Kou Qiang Yi Xue Za Zhi. 1998;16:50-2.
29. Oxitard Capsule - Product - tabletwise.net. (n.d.). Retrieved July 24, 2021, Available:https://www.tabletwise.net/oxitard-capsule
30. Sudarshan R, Annigeri RG, Sree Vijayabala G. Aloe vera in the treatment for oral submucous fibrosis - a preliminary study. J Oral Pathol Med. 2012;41(10):755-61.
31. Joshi SG. Submucous Fibrosis of the Palate and Pillars. Ind J Otolaryngol. 1953;4:1-4.
32. Liu SF, Shen TH, Tang ZG, Su HP, Luo CF. On treatment of oral submucous fibrosis with glucosidorum tripterygium totorum. Beijing J Stomatol. 1999;7:167-169.
33. Tan J, Li YC, Chen A. Clinical research of danxuan koukang on treatment of oral submucous fibrosis. J Traditional Chinese Med University of Hunan. 2006;26:41-43.
34. Pipalia PR, Annigeri RG, Mehta R. Clinico-biochemical evaluation of turmeric with black pepper and niggela sativa in management of oral submucous fibrosis-a double-blind, randomized preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(6):705–712.
35. Kanjani V, Annigeri RG, Revanappa MM, Rani A. Efficacy of spirulina along with different physiotherapeutic modalities in the management of oral submucous fibrosis. Ann Maxillofac Surg. 2019;9(1):23-27.
36. Jain N, Annigeri RG, Pipalia PR. Efficacy of garlic in conjunction with pentoxifylline in the management of oral submucous fibrosis – a preliminary study. Int J Pharm Sci Res. 2016;7(12):5017-23.
37. Cox S, Zoellner H. Physiotherapeutic treatment improves oral opening in oral submucous fibrosis. J Oral Pathol Med. 2009;38:220-6.
38. Kamath VV. Surgical Interventions in Oral Submucous Fibrosis: A Systematic Analysis of the Literature. Journal of maxillofacial and oral surgery, 2015;14(3):521–531.
39. Gondivkar DSM, Gadbail DAR, Sarode DSC. Treatment outcomes of laser therapy in oral submucous fibrosis-a systematic review. J Oral Biol Craniofac Res. 2020;10(3):253-258.

© 2021 Sudarshan; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here: https://www.sdiarticle5.com/review-history/79812